For example, targeting DC-SIGN to enhance IL-10 production could be a strategy to treat chronic inflammatory conditions in animals, such as inflammatory bowel disease or autoimmune skin disorders [50,62,73]. This evidence concerns the gene CD209 and inflammatory bowel disease.